Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT05182775 Recruiting - IgA Nephropathy Clinical Trials

A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The role and related mechanisms of gut microecology in the development and progression of IgA nephropathy were investigated by treating IgA nephropathy subjects with oral probiotic capsules (FMT) combined with metagenomic sequencing and metabolomic analysis.

NCT ID: NCT05097989 Recruiting - Lupus Nephritis Clinical Trials

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Start date: January 14, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years. Safety will be monitored throughout the study.

NCT ID: NCT05083364 Recruiting - IgA Nephropathy Clinical Trials

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G] and IgA Nephropathy [IgAN]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.

NCT ID: NCT05016323 Recruiting - IgA Nephropathy Clinical Trials

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Start date: September 9, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.

NCT ID: NCT05003986 Recruiting - Clinical trials for Focal Segmental Glomerulosclerosis

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

EPPIK
Start date: August 12, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

NCT ID: NCT04858724 Recruiting - IgA Nephropathy Clinical Trials

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.

NCT ID: NCT04833374 Recruiting - IgA Nephropathy Clinical Trials

Steroids Therapy in IgA Nephropathy With Crescents

Start date: May 24, 2021
Phase: Phase 3
Study type: Interventional

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.

NCT ID: NCT04805047 Recruiting - IgA Nephropathy Clinical Trials

SodiUm Restriction by Behavioral Intervention

SURBI
Start date: May 15, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy. The test persons in the intervention group are actively supported to adhere to a restricted sodium diet with a structured education program in combination with regular sodium excretion monitoring.

NCT ID: NCT04716231 Recruiting - IgA Nephropathy Clinical Trials

Atacicept in Subjects With IgA Nephropathy

ORIGIN 3
Start date: May 23, 2023
Phase: Phase 3
Study type: Interventional

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

NCT ID: NCT04684745 Recruiting - IgA Nephropathy Clinical Trials

Open-Label Extension Study of BION-1301 in IgA Nephropathy

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label extension (OLE) study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of BION-1301 in adults with IgA nephropathy